On March 26, 2012, Neurocrine Bio (NBIX) announced results from the company’s phase 2a program with NBI-98854, a VMAT2 inhibitor for the treatment of tardive dyskinesia (TD). We believe...(read more
We’re going to show some of the ultra-shorts and a few select longs that did well on Tuesday to give you an idea as to what‘s going on. The indices had another slam-dunk day on Tuesday, although the futures are higher.
On May 24, 2010, Neurocrine Bio (NBIX) announced that the Daisy PETAL (Study-901) program provided statistically significant results in all top-line primary and secondary ...(read more